3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Colonic Neoplasms
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Locally Advanced Rectal Cancer (LARC)
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Osteosarcoma
1
Neoplasms by Site
1
MMR-D/MSI-H Colorectal Cancers
1
Lung Neoplasms
1
Hodgkin Disease
1
Hepatoblastoma
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fibrolamellar hepatocellular carcinoma
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
36
Magnetic Resonance Spectroscopy
23
Gemcitabine
19
Specimen Handling
15
Nivolumab
12
Carboplatin
12
Surveys and Questionnaires
11
Paclitaxel
11
Cetuximab
11
Early Intervention, Educational
10
Bevacizumab
10
Standard of Care
9
Cyclophosphamide
9
Cisplatin
9
Radiosurgery
8
Methods
8
Fluorouracil
8
Docetaxel
8
Blood Specimen Collection
8
Psychiatric Rehabilitation
7
Pemetrexed
7
sargramostim
6
aldesleukin
6
Taxes
6
Injections
6
Fluorodeoxyglucose F18
6
Educational Status
6
Drug Therapy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
dostarlimab
×
Gastrointestinal
×
Clear all
NCT03250832
2024-04-11
CITRINO
Tesaro, Inc.
Phase 1
Completed
111 enrolled
48 charts